Formation of Interferon-beta (IFN-β) is increased in infections and cancer diseases. Consequently, it is often administered therapeutically. Amongst other things, it prevents formation of new blood vessels within a tumour, thus inhibiting its growth.
Fluorescence image showing a neutrophil (in red) going out of the blood vessel (in green) into a tumour. These immune cells facilitate tumour vessel growth.
Scientists at the Helmholtz Centre for Infection Research (HZI) have now discovered that IFN-β does so by impeding the communication between cancer tissue and immune cells. Their findings, published in the scientific magazine “International Journal of Cancer”, help to understand how this “jamming” can be used therapeutically.
Just like healthy cells, tumour cells need nutrients and oxygen in order to survive. For this reason, a tumour of a certain size has to ensure that it is connected to the blood circulation. In doing this, it is supported by cells of the innate immune system, the neutrophil granulocytes or brief neutrophils, which are supposed to protect the body against pathogens.
Neutrophils normally circulate in the blood until—attracted by so-called chemokines—they enter the tissue where they ingest and destroy intruding pathogens. In addition, these cells are able to trigger the formation of blood vessels. Presumably, this is how they help to repair tissue which has been destroyed by inflammation. However, neutrophils are also able to enter cancer tissue and contribute to its connection to the blood supply. This is probably the reason why detection of numerous neutrophils in a tumour is a sign of unfavourable patient prognosis.
IFN-β is used as a treatment for some tumours such as melanomas and leukaemia. Scientists at the HZI in Braunschweig had shown recently that this messenger molecule can interfere with cancer growth by inhibiting the formation of new blood vessels. However, the way it does so remained a puzzle.
Now, researchers have succeeded in revealing the effect of IFN-β on migration of pro-tumour neutrophils. “We wanted to understand why IFN-β prevents the neutrophils from entering the tumour,” says Dr Jadwiga Jablonska-Koch, scientist in the “Molecular Immunology” department at the HZI. “This would be the way for physicians to improve existing therapies and choose appropriate treatment for the individual patient.”
To this end, the scientists followed the interaction between the cells. Messenger molecules such as chemokines are a means of communication frequently used for this purpose. They are produced by cells and bind to correspondingly shaped surface receptors. In the case of neutrophils, this is the receptor called CXCR2. It binds the chemokines CXCL1, CXCL2 and CXCL5. “We have seen that the concentration of the chemokines in the bone marrow, where the neutrophils originate, is low,” says Dr Siegfried Weiss, head of the department in which Jablonska-Koch works. “On the other hand, we find a high concentration in the tumour, which attracts the neutrophils.” Neutrophils migrate along the chemokine gradient into the tumour and once there, they themselves release the same chemokines in order to attract other neutrophils to obtain more support.
IFN-β interferes with this communication: it makes the cells in the tumour produce fewer chemokines and no chemokine gradient is formed. “That way, fewer neutrophils enter the cancer tissue and fewer new blood vessels are formed,” says Jablonska-Koch. “The tumour is not effectively connected to the vital blood supply and cannot grow efficiently.” For that reason it is of therapeutical benefit to administer IFN-β additionally. “We now better understand why IFN-β helps in some cancers and that it is an important part of the body’s own system for combating tumours,” says Weiss. Their findings could help physicians to assess which patients might profit from administering IFN-β and when neutrophils ought to be an objective of cancer therapy.Original publication
Dr. Birgit Manno | Helmholtz-Zentrum
Tissue-engineered colon from human cells develop different types of neurons
02.10.2015 | Children's Hospital Los Angeles
Big eyes! – MDC Researchers Identify Cause of Inherited Form of Extreme Nearsightedness
02.10.2015 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
The Laser Zentrum Hannover e.V. (LZH) will present how laser-based technologies can contribute to the laboratory of the future at the LABVOLUTION in Hannover in Hall 9, Stand E67/09, from October 6th to 8th, 2015. As a part of the model lab smartLAB, the LZH is showing how additive manufacturing, better known as 3-D printing, can make experimental setups more flexible.
Twelve partners from science and industry are presenting an intelligent and innovative model lab at the special display smartLAB. A part of this intelligent...
Before embarking on a transcontinental journey, jet airplanes fill up with tens of thousands of gallons of fuel. In the event of a crash, such large quantities of fuel increase the severity of an explosion upon impact.
Researchers at Caltech and JPL have discovered a polymeric fuel additive that can reduce the intensity of postimpact explosions that occur during accidents and...
When surgical residents need to practice a complicated procedure to fashion a new ear for children without one, they typically get a bar of soap, carrot or an apple.
To treat children with a missing or under-developed ear, experienced surgeons harvest pieces of rib cartilage from the child and carve them into the framework...
Walking an obstacle course on Earth is relatively easy. Walking an obstacle course on Earth after being in space for six months is not quite as simple. The...
01.10.2015 | Event News
30.09.2015 | Event News
17.09.2015 | Event News
02.10.2015 | Medical Engineering
02.10.2015 | Materials Sciences
02.10.2015 | Trade Fair News